About Vasoactive intestinal polypeptide receptor 2
Vasoactive intestinal polypeptide receptor 2 (VIPR2) is a protein
from Homo sapiens identified by UniProt accession
P41587, 438 residues long.
MolForge cross-references it against 0 known binders and
120 disease associations.
Target properties
| Protein name | Vasoactive intestinal polypeptide receptor 2 |
| UniProt accession | P41587 |
| Gene | VIPR2 |
| Organism | Homo sapiens |
| Length | 438 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (120)
Diseases linked to this target (Open Targets).
- refractive error · score 0.48
- refractive error measurement · score 0.43
- Myopia · score 0.40
- age at onset · score 0.37
- Abnormality of refraction · score 0.32
- bone density · score 0.30
- urate measurement · score 0.30
- pathological myopia · score 0.29
- whooping cough · score 0.17
- myoepithelial tumor · score 0.11
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P41587-F1 | alphafold | PREDICTED | 74.32 | — |
Amino-acid sequence (438 residues)
MRTLLPPALL TCWLLAPVNS IHPECRFHLE IQEEETKCAE LLRSQTEKHK ACSGVWDNIT CWRPANVGET VTVPCPKVFS NFYSKAGNIS KNCTSDGWSE TFPDFVDACG YSDPEDESKI TFYILVKAIY TLGYSVSLMS LATGSIILCL FRKLHCTRNY IHLNLFLSFI LRAISVLVKD DVLYSSSGTL HCPDQPSSWV GCKLSLVFLQ YCIMANFFWL LVEGLYLHTL LVAMLPPRRC FLAYLLIGWG LPTVCIGAWT AARLYLEDTG CWDTNDHSVP WWVIRIPILI SIIVNFVLFI SIIRILLQKL TSPDVGGNDQ SQYKRLAKST LLLIPLFGVH YMVFAVFPIS ISSKYQILFE LCLGSFQGLV VAVLYCFLNS EVQCELKRKW RSRCPTPSAS RDYRVCGSSF SRNGSEGALQ FHRGSRAQSF LQTETSVI
Explore Vasoactive intestinal polypeptide receptor 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets